JP2013049683A - 組合せ - Google Patents
組合せ Download PDFInfo
- Publication number
- JP2013049683A JP2013049683A JP2012230073A JP2012230073A JP2013049683A JP 2013049683 A JP2013049683 A JP 2013049683A JP 2012230073 A JP2012230073 A JP 2012230073A JP 2012230073 A JP2012230073 A JP 2012230073A JP 2013049683 A JP2013049683 A JP 2013049683A
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- pharmaceutically acceptable
- acceptable salt
- combination
- glp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(C)C(CC1)CCC1C(*(C)[C@@](Cc1ccccc1)(C=C)C(OC)=O)=O Chemical compound CC(C)C(CC1)CCC1C(*(C)[C@@](Cc1ccccc1)(C=C)C(OC)=O)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】バルサルタンまたはその医薬上許容される塩および(S)−1−[(3−ヒドロキシ−1−アダマンチル)アミノ]アセチル−2−シアノ−ピロリジンまたはその医薬上許容される塩との組合せ薬剤。
【選択図】なし
Description
(i) AT1レセプターアンタゴニストまたはその医薬上許容される塩、
(ii) (a)インスリン分泌促進剤もしくはその医薬上許容される塩、または
(b)インスリン増感剤もしくはその医薬上許容される塩、および
医薬組成物の場合には、医薬上許容される担体
を含む組合せ、特に医薬組成物に関する。
(i) AT1レセプターアンタゴニストまたはその医薬上許容される塩、
(ii) (a)インスリン分泌促進剤もしくはその医薬上許容される塩、または
(b)インスリン増感剤もしくはその医薬上許容される塩、
を含む組合せの使用に関する。
(i) AT1レセプターアンタゴニストまたはその医薬上許容される塩、
(ii) (a)インスリン分泌促進剤もしくはその医薬上許容される塩、または
(b)インスリン増感剤もしくはその医薬上許容される塩
をともに投与することを含む方法に関する。
(i) AT1レセプターアンタゴニストまたはその医薬上許容される塩、
(ii) (a)インスリン分泌促進剤もしくはその医薬上許容される塩、または
(b)インスリン増感剤もしくはその医薬上許容される塩
の作用の相互作用の向上(特に増強または相乗作用)、例えば1以上の付加的作用、さらに有利な作用、副作用の軽減、有効でない一成分または各成分用量での組合せによる治療作用(特に増強または強力な相乗作用)がある。
バルサルタン、微晶質セルロース、クロスポビドン、コロイド状無水シリカ/コロイド状二酸化珪素/エアロジル200の一部、二酸化珪素およびステアリン酸マグネシウムを拡散ミキサーで予め混合した後、選別ミルにかける。得られた混合物を再び拡散ミキサーで予め混合しローラーコンパクターで粉末成形した後、選別ミルにかける。得られた混合物に残りのコロイド状無水シリカ/コロイド状二酸化珪素/エアロジル200を加え、拡散ミキサーで最終的な混合を行う。全混合物を回転式打錠機にかけ、孔あきパンにてDiolackペールレッドを用いて錠剤をフィルムコーティングする。
カプセル剤:
造粒/乾燥
バルサルタンおよび微晶質セルロースを、流動槽式造粒機にて、純水に溶かしたポビドンおよびラウリル硫酸ナトリウムからなる造粒液を用いて噴霧造粒する。得られた顆粒を流動槽式乾燥機で乾燥させる。
粉砕/配合
乾燥した顆粒をクロスポビドンおよびステアリン酸マグネシウムとともに粉砕する。次にこの粉砕塊を円錐スクリュー型ミキサーで約10分間混合する。
カプセル化
混合したバルク顆粒を温度・湿度条件制御下で空のゼラチン硬カプセルに充填する。充填したカプセルはダスト除去し、目視検査を行い、重量を確認し、品質評価部門に送るまで隔離する。
各120mgのナテグリニドを含有する108,000個の錠剤を以下のように調製する。
組成: ナテグリニド 12.960 kg
ラクトース, NF 30.564 kg
微晶質セルロース, NF 15.336 kg
ポビドン, USP 2.592 kg
クロスカーメロースナトリウム, NF 3.974 kg
コロイド状二酸化珪素, NF 1.382 kg
ステアリン酸マグネシウム, NF 1.231 kg
コーティング:opadry yellow 1.944 kg
純水, USP* Q.S.
*: 処理中に除去される。
調製法:微晶質セルロース、ポビドン、クロスカーメロースナトリウムの一部、ナテグリニドおよびラクトースを高剪断ミキサーで混合した後、純水を用いて造粒する。あるいはまた、微晶質セルロース、ポビドン、クロスカーメロースナトリウムの一部、ナテグリニドおよびラクトースをコレット・グラル(collette gral)造粒機で純水を加えて造粒する。含水顆粒を流動槽式乾燥機で乾燥させ、篩いに通す。コロイド状二酸化珪素および残りのクロスカーメロースナトリウムを混合し、篩いに通し、Vブレンダーにて乾燥顆粒と混合する。ステアリン酸マグネシウムを篩いに通し、Vブレンダー中の混合物と混合した後、全混合物を打錠する。opadry yellowを純水に懸濁し、そのコーティング懸濁液で錠剤をコーティングする。
Claims (2)
- 糖尿病の予防、進行の遅延または処置用医薬の製造のための、(i)バルサルタンまたはその医薬上許容される塩および(ii)(S)−1−[(3−ヒドロキシ−1−アダマンチル)アミノ]アセチル−2−シアノ−ピロリジンまたはその医薬上許容される塩の組合せの使用。
- 微量アルブミン尿症の改善用医薬の製造のための、(i)バルサルタンまたはその医薬上許容される塩および(ii)(S)−1−[(3−ヒドロキシ−1−アダマンチル)アミノ]アセチル−2−シアノ−ピロリジンまたはその医薬上許容される塩の組合せの使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64364100A | 2000-08-22 | 2000-08-22 | |
US09/643,641 | 2000-08-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002520854A Division JP2004514654A (ja) | 2000-08-22 | 2001-08-20 | 組合せ |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015133314A Division JP2015205909A (ja) | 2000-08-22 | 2015-07-02 | 組合せ |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2013049683A true JP2013049683A (ja) | 2013-03-14 |
Family
ID=24581689
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002520854A Withdrawn JP2004514654A (ja) | 2000-08-22 | 2001-08-20 | 組合せ |
JP2009224224A Withdrawn JP2010043101A (ja) | 2000-08-22 | 2009-09-29 | 組合せ |
JP2012230073A Withdrawn JP2013049683A (ja) | 2000-08-22 | 2012-10-17 | 組合せ |
JP2015133314A Pending JP2015205909A (ja) | 2000-08-22 | 2015-07-02 | 組合せ |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002520854A Withdrawn JP2004514654A (ja) | 2000-08-22 | 2001-08-20 | 組合せ |
JP2009224224A Withdrawn JP2010043101A (ja) | 2000-08-22 | 2009-09-29 | 組合せ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015133314A Pending JP2015205909A (ja) | 2000-08-22 | 2015-07-02 | 組合せ |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040034065A1 (ja) |
EP (3) | EP1980249A3 (ja) |
JP (4) | JP2004514654A (ja) |
AR (1) | AR033390A1 (ja) |
AT (1) | ATE399010T1 (ja) |
AU (1) | AU2001287698A1 (ja) |
CL (1) | CL2009001899A1 (ja) |
CY (1) | CY1111698T1 (ja) |
DE (1) | DE60134575D1 (ja) |
DK (1) | DK1351683T3 (ja) |
MY (1) | MY141012A (ja) |
PE (1) | PE20020617A1 (ja) |
PT (1) | PT1351683E (ja) |
TW (3) | TWI327468B (ja) |
WO (1) | WO2002015933A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
EP1483232A1 (en) * | 2002-03-11 | 2004-12-08 | Novartis AG | Salts of nateglinide |
WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CN100438911C (zh) * | 2002-12-27 | 2008-12-03 | 武田药品工业株式会社 | 体重增加抑制剂 |
CA2522318C (en) * | 2003-04-15 | 2011-09-13 | Sankyo Company Limited | Drug for preventing or treating angiogenic eye diseases |
US20070054947A1 (en) * | 2003-05-16 | 2007-03-08 | Cohn Jay N | Pharmaceutical composition comprising valsartan |
WO2005092319A1 (en) * | 2004-03-29 | 2005-10-06 | Ranbaxy Laboratories Limited | Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant |
AU2005243214B2 (en) | 2004-04-29 | 2011-07-07 | U.S. Smokeless Tobacco Company Llc | Nicotiana nucleic acid molecules and uses thereof |
JP4914714B2 (ja) * | 2004-05-11 | 2012-04-11 | キッセイ薬品工業株式会社 | 脂質代謝異常の予防または治療用医薬組成物 |
WO2005117591A2 (en) * | 2004-05-28 | 2005-12-15 | Andrx Labs Llc | Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist |
CA2583768A1 (en) * | 2004-10-07 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Agent for prophylaxis or treatment of metabolic syndrome |
JP2007099764A (ja) * | 2005-09-09 | 2007-04-19 | Ajinomoto Co Inc | 血糖低下剤 |
WO2010122927A1 (ja) * | 2009-04-20 | 2010-10-28 | 第一三共株式会社 | 糖尿病由来神経再生遅延の予防又は治療のための医薬 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09510225A (ja) * | 1994-03-17 | 1997-10-14 | チバ−ガイギー アクチェンゲゼルシャフト | バルサルタンを用いる糖尿病性ネフロパシーの治療 |
JPH11315034A (ja) * | 1998-03-04 | 1999-11-16 | Takeda Chem Ind Ltd | アンギオテンシンii拮抗作用を有する化合物の徐放性製剤、その製造法および用途 |
WO2000002543A2 (en) * | 1998-07-10 | 2000-01-20 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
JP2000506540A (ja) * | 1996-06-27 | 2000-05-30 | ノバルティス アクチエンゲゼルシャフト | バルサルタンの固体経口剤形 |
WO2000034241A1 (en) * | 1998-12-10 | 2000-06-15 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
WO2000045818A1 (en) * | 1999-02-06 | 2000-08-10 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
JP2004514654A (ja) * | 2000-08-22 | 2004-05-20 | ノバルティス アクチエンゲゼルシャフト | 組合せ |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
EP0955294B1 (en) | 1989-06-14 | 2003-09-24 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid |
ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
EP0443983B1 (de) | 1990-02-19 | 1996-02-28 | Ciba-Geigy Ag | Acylverbindungen |
NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
AU660930B2 (en) | 1991-06-21 | 1995-07-13 | Novo Nordisk A/S | (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid |
DE69217762T2 (de) | 1991-07-30 | 1997-10-09 | Ajinomoto Kk | Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
TW226375B (ja) | 1991-10-24 | 1994-07-11 | American Home Prod | |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
JP3883205B2 (ja) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | アンギオテンシン▲ii▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療 |
US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
RU2188013C2 (ru) * | 1996-04-05 | 2002-08-27 | Такеда Кемикал Индастриз, Лтд. | Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
FR2778103A1 (fr) * | 1998-04-29 | 1999-11-05 | Sanofi Sa | Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii |
DE69919156T2 (de) * | 1998-05-11 | 2005-11-03 | Takeda Pharmaceutical Co. Ltd. | Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung |
TR200200515T2 (tr) * | 1999-08-30 | 2002-11-21 | Aventis Pharma Deutschland Gmbh | Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması. |
TWI302149B (en) * | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
WO2001082916A2 (en) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
-
2001
- 2001-08-17 AR ARP010103950A patent/AR033390A1/es not_active Application Discontinuation
- 2001-08-17 PE PE2001000825A patent/PE20020617A1/es not_active Application Discontinuation
- 2001-08-20 WO PCT/EP2001/009587 patent/WO2002015933A2/en active IP Right Grant
- 2001-08-20 EP EP08154993A patent/EP1980249A3/en not_active Withdrawn
- 2001-08-20 TW TW097122770A patent/TWI327468B/zh not_active IP Right Cessation
- 2001-08-20 US US10/362,340 patent/US20040034065A1/en not_active Abandoned
- 2001-08-20 PT PT01967289T patent/PT1351683E/pt unknown
- 2001-08-20 JP JP2002520854A patent/JP2004514654A/ja not_active Withdrawn
- 2001-08-20 DK DK01967289T patent/DK1351683T3/da active
- 2001-08-20 TW TW090120391A patent/TWI315197B/zh not_active IP Right Cessation
- 2001-08-20 AU AU2001287698A patent/AU2001287698A1/en not_active Abandoned
- 2001-08-20 AT AT01967289T patent/ATE399010T1/de active
- 2001-08-20 DE DE60134575T patent/DE60134575D1/de not_active Expired - Lifetime
- 2001-08-20 EP EP01967289A patent/EP1351683B1/en not_active Expired - Lifetime
- 2001-08-20 EP EP09171372A patent/EP2138175A3/en not_active Withdrawn
- 2001-08-20 TW TW097122772A patent/TWI327469B/zh not_active IP Right Cessation
- 2001-08-21 MY MYPI20013925A patent/MY141012A/en unknown
-
2008
- 2008-09-24 CY CY20081101043T patent/CY1111698T1/el unknown
-
2009
- 2009-09-24 CL CL2009001899A patent/CL2009001899A1/es unknown
- 2009-09-29 JP JP2009224224A patent/JP2010043101A/ja not_active Withdrawn
-
2012
- 2012-10-17 JP JP2012230073A patent/JP2013049683A/ja not_active Withdrawn
-
2015
- 2015-07-02 JP JP2015133314A patent/JP2015205909A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09510225A (ja) * | 1994-03-17 | 1997-10-14 | チバ−ガイギー アクチェンゲゼルシャフト | バルサルタンを用いる糖尿病性ネフロパシーの治療 |
JP2000506540A (ja) * | 1996-06-27 | 2000-05-30 | ノバルティス アクチエンゲゼルシャフト | バルサルタンの固体経口剤形 |
JPH11315034A (ja) * | 1998-03-04 | 1999-11-16 | Takeda Chem Ind Ltd | アンギオテンシンii拮抗作用を有する化合物の徐放性製剤、その製造法および用途 |
WO2000002543A2 (en) * | 1998-07-10 | 2000-01-20 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
WO2000034241A1 (en) * | 1998-12-10 | 2000-06-15 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
WO2000045818A1 (en) * | 1999-02-06 | 2000-08-10 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
JP2004514654A (ja) * | 2000-08-22 | 2004-05-20 | ノバルティス アクチエンゲゼルシャフト | 組合せ |
Non-Patent Citations (6)
Title |
---|
JPN6012033640; 臨床医薬, 1996, Vol.12, No.9, pp.1766-1772 * |
JPN6012033642; Progress in Medicine, 2000.06, Vol.20, No.6, pp.1253-1257 * |
JPN6012033644; Diabetes Journal, 2000.06.01, Vol.28, No.2, pp.7-13 * |
JPN6012033645; Current Therapeutic Research, 1999, Vol.60, No.12, pp.650-660 * |
JPN6012033647; J. American college of cardiology, 1999, Vol.33, No.2, Suppl.A, pp.299A * |
JPN6015007661; J. Pharmacol. Exp. Ther., 2008, Vol.327, No.3, pp.683-691 * |
Also Published As
Publication number | Publication date |
---|---|
US20040034065A1 (en) | 2004-02-19 |
TW200838503A (en) | 2008-10-01 |
EP1351683B1 (en) | 2008-06-25 |
CY1111698T1 (el) | 2015-10-07 |
EP1980249A2 (en) | 2008-10-15 |
JP2015205909A (ja) | 2015-11-19 |
AR033390A1 (es) | 2003-12-17 |
TWI315197B (en) | 2009-10-01 |
EP1351683A2 (en) | 2003-10-15 |
TWI327468B (en) | 2010-07-21 |
ATE399010T1 (de) | 2008-07-15 |
AU2001287698A1 (en) | 2002-03-04 |
WO2002015933A2 (en) | 2002-02-28 |
PT1351683E (pt) | 2008-09-18 |
CL2009001899A1 (es) | 2010-02-12 |
TWI327469B (en) | 2010-07-21 |
DE60134575D1 (de) | 2008-08-07 |
JP2010043101A (ja) | 2010-02-25 |
EP1980249A3 (en) | 2010-04-28 |
PE20020617A1 (es) | 2002-08-05 |
TW200843741A (en) | 2008-11-16 |
JP2004514654A (ja) | 2004-05-20 |
MY141012A (en) | 2010-02-25 |
EP2138175A2 (en) | 2009-12-30 |
DK1351683T3 (da) | 2008-10-20 |
WO2002015933A3 (en) | 2003-08-14 |
EP2138175A3 (en) | 2010-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015205909A (ja) | 組合せ | |
EP1743655B1 (en) | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents | |
EP1507529B1 (en) | Combination comprising valsartan, amlodipine and hydrochlorothiazide | |
US20090131404A1 (en) | Combinations | |
AU2003209745B2 (en) | Combination comprising an HMG-CoA reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer | |
NZ531929A (en) | Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism | |
US20080261864A1 (en) | Combination of nateglinide or repaglinide with at least one further antidiabetic compound | |
US20030114389A1 (en) | Combination of organic compounds | |
US8106081B2 (en) | Combination of organic compounds useful for treating diabetes | |
US20070093431A1 (en) | Combination of organic compounds | |
AU2007201989A1 (en) | Combination comprising an HMG-CoA reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140407 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140410 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140502 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140611 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140718 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140723 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20140827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140827 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150812 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150903 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151023 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20160205 |